Roman GALETTO,Agnes GOUBLE,Stephanie GROSSE,Cécile SCHIFFER-MANNIOUI,Laurent POIROT,Andrew SCHARENBERG,Julianne SMITH
申请号：
US14889686
公开号：
US20160120905A1
申请日:
2014.05.13
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
